remynd Alternatives & Competitors
12 companies similar to remynd
Vivodyne
We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on...
Philadelphia, United Stat...
VALANX Biotech
Safer, more effective ADCs and protein-drug-conjugates with GoldenSite™ technology
Klosterneuburg, Austria
Quris AI
Leading the AI-Pharma Revolution
Boston, United States
Transition Bio, Inc.
The only end-to-end condensate drug discovery platform built on molecular insights.
Cambridge, United States
Track all remynd competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Alioth Biotech
Your Reliable Partner in Pharma Filtration Processing
China
AQEMIA
Scale drug discovery with quantum-inspired physics and generative AI
Paris, France
Fathom Therapeutics
The molecular frontier
New York, United States
Kimia Therapeutics
Berkeley, United States
Avilar Therapeutics
Pioneering the discovery and development of extracellular protein degraders.
Waltham, United States
Enhanced Genomics
Discover. Target. Cure.
Cambridge, United Kingdom
Peptone
Drugging disordered proteins with physics and AI
London, United Kingdom
Inventia Life Science
Advanced cell models made easy for high impact discovery
Australia
About remynd
Development of oral treatments for neurodegenerative diseases, Contract Research Organization services, Proof-of-concept studies in mouse models
Pharmaceutical companies, Biopharmaceutical researchers, Drug developers, Healthcare stakeholders
B2B, B2D
Licensing, Service Fee, Project Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches remynd and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at remynd on 23 Feb 2026. The 12 companies listed here were last checked between 11 Mar 2026 and 25 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.